A patient with a stage IB (cT2aN0M0) <i>KIF5B-RET</i> fusion-positive NSCLC received 8 weeks of neoadjuvant selpercatinib at 160 mg twice daily followed by surgery. This evidence concerns the gene RET and non-small cell lung carcinoma.